Outsourced Pharma Capacity 2025 -Curia Biologics

<pBill Hermans, site head at Curia’s Hopkinton, MA facility discusses capabilities including:

• Wholly-owned proprietary CHO-GSN cell lines
• Experience with IgG, fusion proteins, bispecific antibodies, and monoclonal antibodies
• 9-12 month timeline from CLD to phase I drug substance
• cGMP batch sizes up to 2,000 L